Author

Gwendolyn Fate

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:mouse· 1

Frequent Co-Authors

A. Kenneth MacLeodiD· 1 shared Alpha A. LeeiD· 1 shared Andrew Wells· 1 shared Annette von DelftiD· 1 shared Anthony Simon· 1 shared Benjamin PerryiD· 1 shared Blake H. BalcombiD· 1 shared Briana Lynn McGoverniD· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperPharmacology & Toxicology

A. Kenneth MacLeodORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Open-science discovery of DNDI-6510, a compound that addresses genotoxic and metabolic liabilities of the COVID Moonshot SARS-CoV-2 Mpro lead inhibitor

Ed Griffen, D. Fearon, Briana Lynn McGovern, L. Koekemoer, Blake H. Balcomb, Tamás Szommer, Gwendolyn Fate, Ralph P. Robinson, Bruce A. Lefker, Shirly Duberstein, Noa Lahav, Stéphanie Braillard, Laura Vangeel, Manon Laporte, Fabienne Burgat Charvillon, , Annette von Delft

This paper describes the optimization of a SARS-CoV-2 Mpro inhibitor to address genotoxic and metabolic liabilities, leading to improved in vivo efficacy and exposure.

bioRxiv · Jun 16, 2025 · PreprintPharmacology & Toxicology